Normal View Dyslexic View

Plain balloon angioplasty with or without bare-metal stenting versus drug-coated balloon angioplasty with or without bare-metal stenting versus primary drug-eluting stenting in patients requiring femoropopliteal, with or without infrapopliteal, endovascular revascularization for chronic limb-threatening ischaemia: BASIL-3 within-trial health economic analysis

20 May 2026
Vascular
BJSA
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
Javed M, Kigozi J, Moakes CA, Bate GR, Hall JA, Deeks JJ, et al.
BJS 2026; 113: znaf274.
Some 481 patients were included in the cost-utility analysis, where the probability of drug-coated balloon angioplasty being cost-effective at £20 000 per QALY was 52 per cent and 76 per cent, respectively. Differences in cost and quality-adjusted life year gains between drug-coated balloon angioplasty and drug-eluting stent with bare metal stent were not significant.
Comment: Drug-coated balloon angioplasty and drug-eluting stents show similar outcomes to bare metal stents, but they are not cost-effective.
Info
Copied!